Circulating Serum Level of Visfatin in Patients with Endometrial Cancer

<table class="table-group" id="tab6"><tr><td><table class="table"><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr class="thead"><td class="align_left"> </td><td class="align_center">Sensitivity</td><td class="align_center">Specificity</td></tr><tr><td class="thead-hr" colspan="3"><hr/></td></tr><tr><td class="align_left">Visfatin</td><td class="align_center">88%</td><td class="align_center">79%</td></tr><tr><td class="align_left">Visfatin PM</td><td class="align_center">85%</td><td class="align_center">73%</td></tr><tr><td class="align_left">Visfatin M</td><td class="align_center">90%</td><td class="align_center">83%</td></tr><tr class="table-tr"><td colspan="3"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>PM: premenopausal; M: postmenopausal.<br/></td></tr></table>

Sensitivity and specificity for visfatin.

BioMed Research International

tab6

Table 6

Table 6: Circulating Serum Level of Visfatin in Patients with Endometrial Cancer 